| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation (NCT05102292) | Shanghai Henlius Biotech | 2021-12-10 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT04579757) | Hutchmed | 2021-03-05 |
| Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) (NCT04574817) | Taizhou Hanzhong biomedical co. LTD | 2020-12-28 |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (NCT04400474) | Grupo Espanol de Tumores Neuroendocrinos | 2020-10-07 |
| Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer (NCT04420754) | AffyImmune Therapeutics, Inc. | 2020-09-28 |
| Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer (NCT04552769) | Stanford University | 2020-09-10 |
| Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer (NCT04238624) | Memorial Sloan Kettering Cancer Center | 2020-01-20 |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer (NCT03085056) | Memorial Sloan Kettering Cancer Center | 2017-03-15 |
| Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer (NCT02688608) | Saad A Khan | 2016-10-01 |
| Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (NCT02726503) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2016-04-04 |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer (NCT02244463) | Dana-Farber Cancer Institute | 2015-07-01 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies (NCT02404441) | Novartis Pharmaceuticals | 2015-04-27 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (NCT01701349) | Mateon Therapeutics | 2015-03-01 |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer (NCT02152137) | Alliance for Clinical Trials in Oncology | 2014-12-30 |
| interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) (NCT01774279) | Velindre NHS Trust | 2013-06-01 |
| A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) (NCT01240590) | National Cancer Institute (NCI) | 2011-01-26 |
| A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel (NCT00603941) | Daiichi Sankyo | 2008-01-01 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (NCT00507429) | Mateon Therapeutics | 2007-08-01 |
| Review of Multimodality Management of Anaplastic Thyroid Cancer (NCT00280852) | Alberta Health services | 2006-01-01 |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer (NCT00126568) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer (NCT00095693) | National Cancer Institute (NCI) | 2004-10-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |